The 7-Plex ProcartaPlex Human Heart Disease Panel allows cardiovascular research by analyzing seven protein targets in a single well using Luminex xMAP technology. Simultaneous detection of these targets can help to...
The 7-Plex ProcartaPlex Human Heart Disease Panel allows cardiovascular research by analyzing seven protein targets in a single well using Luminex xMAP technology. Simultaneous detection of these targets can help explore diseases such as coronary heart disease and hypertension. The panel is supplied in a ready-to-use format with individual vials of capture and detection reagents formulated at a concentration of 1X, requiring less pipeting and experimental configuration. It cannot be associated with simplexes or other panels. It completes the heart remodeling panel ProcartaPlex (ref. EPX080-15819-901) which provides eight additional protein targets in the same research area.
ProcartaPlex preconfigured panels are widely tested for combination, interference and cross-reactivity of analytes to provide the highest level of validation and accuracy. All ProcartaPlex panels are supplied with the reagents necessary to perform the dosage.
Target list [microbille region]: cardiotropin-1 (CTF-1) [12], CKMB [63], FABP-3 [43], GDF-15 [33], myoglobin [47], NTproBNP [48], troponin I (TNI) [54]
ProcartaPlex immunoassays are based on the principles of an ELISA sandwich that uses two highly specific antibodies binding to different epitopes of a protein to simultaneously quantify all protein targets using a Luminex instrument. ProcartaPlex multiplex assays require only 25 µl plasma or serum, or 50 µl cell culture supernatant, and only four hours to obtain analyzed results.
The characteristics include:
• Reproducible and reliable results — validated in panel according to the highest industry standard, with tests for protein target combinationability and cross-reactivity
•More results per sample — allows multiple protein targets to be achieved simultaneously in a single sample of 25–50 µl
•High-reference multiplexing platform with well established Luminex technology for protein detection and quantification
ProcartaPlex assays use Luminex xMAP (multianalyte profiling) technology for simultaneous detection and quantification of up to 80 protein targets in a single 25–50 µl sample — plasma, serum, cell culture supernatant and other body fluids.
Luminex balls in the ProcartaPlex assay are coloured internally with precise proportions of red and infrared fluorophores to create specific signatures that can be identified by Luminex xMAP detection systems (e.g. Luminex 200, Flexmap 3D and MAGPIX). Like the ELISA sandwich assay, ProcartaPlex uses paired antibody pairs to identify the protein of interest. In multiplexed assays, each single spectral microbead is marked with antibodies specific to a single target protein and the bound proteins are identified with biotinyl antibodies and streptavidine–R-phycoerythrin (RPE). The combination of protein-specific antibodies with a separate microbead allows for the analysis of several targets in a single well.
The most significant difference between ProcartaPlex and ELISA is that the capture antibody in the ProcartaPlex assay is combined with a microbead and is not absorbed into the microplate well, so that the ProcartaPlex assay reagents are floating in the solution. For detection purposes, Luminex 200, for example, contains two lasers: one to distinguish the spectral signature from each microbead and one to quantify the amount of fluorescence of RPE. The latter is proportional to the amount of protein present in the sample. Multiplex ProcartaPlex assays can profile more target proteins using a significantly smaller sample at the same time as it is necessary to make a traditional ELISA sandwich.
ProcartaPlex multiplex panels are available in several formats for six species (human, mouse, rat, non-human primate, porcine and canine).